- Home
- XNCR vs MLTX Comparison
XNCR vs MLTX Comparison
Compare XNCR & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- MLTX
- Stock Information
- Founded
- XNCR 1997
- MLTX 2021
- Country
- XNCR United States
- MLTX Switzerland
- Employees
- XNCR N/A
- MLTX N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- MLTX Health Care
- Exchange
- XNCR Nasdaq
- MLTX Nasdaq
- Market Cap
- XNCR 547.8M
- MLTX 595.6M
- IPO Year
- XNCR 2013
- MLTX N/A
- Fundamental
- Price
- XNCR $13.61
- MLTX $10.61
- Analyst Decision
- XNCR Buy
- MLTX Buy
- Analyst Count
- XNCR 11
- MLTX 9
- Target Price
- XNCR $22.20
- MLTX $37.63
- AVG Volume (30 Days)
- XNCR 1.3M
- MLTX 10.8M
- Earning Date
- XNCR 11-05-2025
- MLTX 11-06-2025
- Dividend Yield
- XNCR N/A
- MLTX N/A
- EPS Growth
- XNCR N/A
- MLTX N/A
- EPS
- XNCR N/A
- MLTX N/A
- Revenue
- XNCR $146,929,000.00
- MLTX N/A
- Revenue This Year
- XNCR $23.31
- MLTX N/A
- Revenue Next Year
- XNCR N/A
- MLTX N/A
- P/E Ratio
- XNCR N/A
- MLTX N/A
- Revenue Growth
- XNCR N/A
- MLTX N/A
- 52 Week Low
- XNCR $6.92
- MLTX $5.95
- 52 Week High
- XNCR $27.24
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- XNCR 88.43
- MLTX 25.77
- Support Level
- XNCR $11.36
- MLTX $8.18
- Resistance Level
- XNCR $13.07
- MLTX $7.48
- Average True Range (ATR)
- XNCR 0.63
- MLTX 1.65
- MACD
- XNCR 0.16
- MLTX -1.42
- Stochastic Oscillator
- XNCR 94.92
- MLTX 8.20
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.